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Aims The aim of this study was to investigate whether prolonged and dispersed myocardial contraction duration assessed
by tissue Doppler imaging (TDI) may serve as risk markers for cardiac events (documented arrhythmia, syncope, and
cardiac arrest) in patients with long QT syndrome (LQTS).
Methods
and results
Seventy-three patients with genetically conﬁrmed LQTS (nine double- and 33 single-mutation carriers with previous
cardiac events and 31 single-mutation carriers without events) were studied. Myocardial contraction duration was
prolonged in each group of LQTS patients compared with 20 healthy controls (P , 0.001). Contraction duration
was longer in single-mutation carriers with previous cardiac events compared with those without (0.46+0.06 vs.
0.40+0.06 s, P ¼ 0.001). Prolonged contraction duration could better identify cardiac events compared with cor-
rected QT (QTc) interval in single-mutation carriers [area under curve by receiver-operating characteristic analysis
0.77 [95% conﬁdence interval (95% CI) 0.65–0.89] vs. 0.66 (95% CI 0.52–0.79)]. Dispersion of contraction was more
pronounced in single-mutation carriers with cardiac events compared with those without (0.048+0.018 vs.
0.031+0.019 s, P ¼ 0.001).
Conclusion Dispersion of myocardial contraction assessed by TDI was increased in LQTS patients. Prolonged contraction dur-
ation was superior to QTc for risk assessment. These new methods can easily be implemented in clinical routine and
may improve clinical management of LQTS patients.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
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Introduction
The long QT syndrome (LQTS) is a genetic disorder characterized
by prolonged ventricular repolarization that predisposes to life-
threatening arrhythmias.
1 The pathophysiology behind the arrhyth-
mias in LQTS is not precisely deﬁned. Possible mechanisms include
early after-depolarizations (EADs) and dispersion of myocardial
repolarization.
Fifty years after its initial description,
2–4 approaches for risk
stratiﬁcation are insufﬁciently deﬁned. Risk stratiﬁcation today is
based on history of syncope, genotype, gender, and corrected
QT (QTc) interval.
1,5 Prolonged QTc is a marker of prolonged
action potential duration which is associated with a prolonged
left ventricular (LV) contraction.
6–8 Electrocardiogram (ECG)
has limited abilities to detect regional differences in LV electrical
pattern. A relationship between motion abnormalities of the LV
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doi:10.1093/eurheartj/ehn466assessed by echocardiography and syncope or cardiac arrest in
LQTS patients was ﬁrst indicated by Schwartz and colleagues.
9,10
Tissue Doppler imaging (TDI) has been established as a clinical
method for the quantiﬁcation of regional myocardial function.
11
The diagnostic value of this new modality has not been previously
described in LQTS patients.
The objective of this study was to determine whether myocardial
velocities, time-intervals, or strains by TDI could be a tool for iden-
tifyinghigh-riskindividualsinLQTSpatients.Highriskwasdeﬁnedas
patients with a previous cardiac event, i.e. documented arrhythmia,
syncope, or cardiac arrest. Our hypothesis was that prolonged
action potentials will cause a prolonged myocardial contraction
that can be assessed by TDI. Furthermore, we hypothesized that
myocardial mechanical dispersion can be assessed as heterogeneity
in the regional myocardial contraction duration by TDI.
Methods
Long QT syndrome patients
Seventy-three patients with molecularly deﬁned LQTS were included
in this study (Figure 1). None of the LQTS patients had structural
heart disease of other origin or were ventricularly paced. All 73
LQTS mutation carriers were genotyped: 44 LQT1, 18 LQT2, 1
LQT3, 1 LQT5, and nine double-mutation carriers. Double-mutation
carriers were considered a separate category and were analysed
separately.
Long QT syndrome single-mutation carriers
Sixty-four patients were single-mutation carriers of an
LQTS-associated mutation. Of the single-mutation carriers, 33 (52%)
had a history of documented arrhythmia, syncope, or cardiac arrest,
here deﬁned as ‘symptomatic’. All symptomatic and three asympto-
matic single-mutation carriers received therapy with beta-blockers
(n ¼ 36). In addition to beta-blocker therapy, three single-mutation
carriers were treated with an ICD and three with atrial pacemaker.
In addition, six single-mutation carriers were studied with ECG and
echocardiography but deemed ineligible for inclusion. One of these six
was an LQT1 patient who received chemotherapy owing to malignant
disease and developed cardiomyopathy with reduced LV function. Five
asymptomatic mutation carriers ,15 years of age were ineligible for
inclusion. We could not exclude future cardiac events in these
young individuals and their status as asymptomatic in this study
would therefore be inaccurate.
Long QT syndrome double-mutation carriers,
Jervell and Lange-Nielsen syndrome
Nine patients were double-mutation carriers of an LQTS-associated
mutation and had clinically Jervell and Lange-Nielsen syndrome
(JLNS) with additional deafness. All JLNS patients had experienced
repeated cardiac events and were treated with beta-blockers. In
addition, one JLNS patient was treated with left sympathetic denerva-
tion, two with an ICD, and three with atrial pacemaker.
Control groups
Healthy individuals
Twenty healthy individuals were age- and sex-matched and recruited
from hospital staff. All had normal clinical examination, ECG, QTc,
and echocardiography.
Individuals on beta-blocker therapy
Since 64% of the LQTS patients were on beta-blocker therapy, we
included 18 individuals on beta-blocker therapy for comparison.
They were treated with beta-blockers for suspected angina pectoris
from the referral institution ahead of an elective coronary angiography.
They were included in our beta-blocker control group after ﬁndings of
a normal coronary angiography at our hospital. In addition, normal
ﬁndings were required for the clinical examination, ECG, QTc, and
echocardiography. Beta-blocker treatment was discontinued in all
these patients after the examination at our hospital.
Figure 1 Algorithm of study participants. The groups of healthy individuals and individuals on beta-blocker therapy represent the control
groups.
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Electrocardiogram
Twelve-lead ECG was obtained in all participants, either before or
after echocardiography. The QT interval was corrected for heart
rate using Bazett’s formula.
12
Echocardiographic studies
The echocardiographic studies were performed using Vivid 7 (GE
Healthcare, Horten, Norway) and analysed with commercially available
software (EchoPAC
w, GE). By conventional 2D echocardiography,
we assessed LV ejection fraction ad modum Simpson. Systolic time
interval was assessed by Doppler ﬂow velocity measurement as the
time from start of R on ECG to aortic valve closure.
Tissue Doppler imaging
Two-dimensional TDI recording of the LV was obtained from the
basal and mid-segments from apical four-chamber, two-chamber, and
long-axis views. Three cycles were analysed and the image frame
rate obtained in this study was 124+29 frames/s. The following
parameters from TDI were assessed:
(i) Peak ejection velocity.
(ii) Peak myocardial velocity after aortic valve closure—post-ejection
velocity (PEV). PEV was deﬁned as the peak of the upstroke of
the biphasic spike after ejection. In individuals without post-
systolic shortening, this spike can occur below the zero line
(Figure 2).
(iii) Maximum PEV in absolute value, negative or positive, was
measured and the anatomical location was noted in each
participant.
(iv) Myocardial contraction duration was measured in the basal septal
segment and deﬁned as the time from start of R on ECG to end
of PEV (zero-crossing) if positive PEV was present. If no positive
PEV was present, contraction duration was deﬁned as the time
from start of R on ECG to zero-crossing of the decreasing
velocity slope in end-systole (Figure 2).
(v) Contraction duration of the basal segment of the six LV wall pos-
itions was measured and the standard deviation of these values
calculated as a parameter of mechanical dispersion of contraction
(Figure 3).
(vi) In diastole, we measured the time from start of R to onset of E0
and peak E0.
(vii) Contraction duration was measured in strain traces as the time
from start of R on ECG to peak negative strain (Figure 2).
Efforts were made to ensure good image quality in each patient. TDI
parameters could be assessed in 98% of the myocardial segments in
LQTS mutation carriers and in 94% of the subjects in the other
groups. The primary analysis was done unblinded by a single observer
and repeated in a blinded fashion 4 months later (K.H.H.). All analyses
were repeated by an independent observer (T.E.), blinded to patient
identity and other data. The authors had full access to the data and
take responsibility for its integrity. All authors have read and agree
to the manuscript as written.
Statistical analyses
Data were presented as mean+standard deviation. Comparisons of
means were analysed by ANOVA with the Bonferroni post hoc correc-
tion for multiple comparisons (SPSS 15.0). Receiver-operating charac-
teristic (ROC) curves were constructed to determine the sensitivity
and speciﬁcity of the parameters—QTc, myocardial contraction dur-
ation, and PEV—to identify cardiac events (documented arrhythmia,
syncope, or cardiac arrest) in LQTS single-mutation carriers. For con-
traction duration and PEV, the optimal cut-offs were deﬁned as the
value of the ROC curve which was closest to the upper left corner
(Figure 4). The reliability of the cut-off values was validated using boot-
strap resampling (n ¼ 1000),
13 and 95% conﬁdence intervals (95% CIs)
based on bootstrap percentiles were presented. The statistical soft-
ware package R (version 2.5.1) was used for bootstrap analysis. For
QTc, we used the established cut-off value of 0.46 s.
14 For the area
under the ROC curve, 95% CIs were presented. Reproducibility was
expressed as intraclass correlation coefﬁcient for single measures.
For all statistical analyses, P-values were two-sided, with results less
than 0.05 considered signiﬁcant.
Figure 3 Myocardial mechanical dispersion by tissue Doppler
imaging. The left panels show velocity curves from four different
segments in a healthy individual in four-chamber (upper left) and
apical long-axis views (lower left). The right panels show velocity
curves from a symptomatic long QT syndrome patient. White
markers show the shortest and the longest contraction durations
in each person. The difference in contraction duration is 0.03 s in
the healthy individual and 0.12 s in the long QT syndrome patient
and is consistent with the mechanical dispersion of contraction.
Figure 2 Myocardial contraction duration by tissue Doppler
imaging. Myocardial velocities (upper panels) and strains (lower
panels) from a healthy individual (left) and a long QT syndrome
patient (right).
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All groups of LQTS mutation carriers were comparable with
healthy individuals with respect to age and heart rate (Table 1).
The QTc was prolonged in each of the LQTS groups compared
with the control groups. EF and peak ejection velocity, as
markers of systolic function, were normal in all LQTS groups, in
healthy individuals and in individuals on beta-blocker therapy
(Table 1).
Echocardiographic analysis by tissue
Doppler imaging
Contraction duration was assessed in both myocardial velocity and
strain traces with consistent results.
Long QT syndrome single-mutation carriers
Contraction duration was signiﬁcantly longer in symptomatic
LQTS single-mutation carriers compared with asymptomatic car-
riers and healthy individuals (P ¼ 0.001) (Table 1). In contrast to
healthy individuals, LQTS mutation carriers showed contraction
durations that exceeded the time to aortic valve closure. Patients
on beta-blocker therapy did not have prolonged contraction dur-
ation. Therefore, the prolonged contraction duration in LQTS
mutation carriers could not be attributed to the use of beta-
blocker medication. Mechanical dispersion, assessed as standard
deviation of contraction duration, was signiﬁcantly greater in
LQTS single-mutation carriers compared with healthy individuals
(P , 0.001) and compared with individuals on beta-blocker therapy
(P, 0.001). In addition, mechanical dispersion was signiﬁcantly
greater in symptomatic compared with asymptomatic single-mutation
carriers (P ¼ 0.001). The correlation between contraction duration
and QTc was signiﬁcant (R ¼ 0.43, P , 0.001).
A marked PEV was observed in LQTS mutation carriers and was
signiﬁcantly greater than PEV found in healthy individuals (Figure 2,
Table 1). In addition, the maximum PEV in symptomatic LQTS
single-mutation carriers was greater than that in asymptomatic
LQTS mutation carriers (P ¼ 0.001). The maximum PEV was
most often localized in the posterior part of the LV septum (n ¼
34), but was also found in the anterior part of the septum (n ¼
17), in the anterior wall (n ¼ 12), in the lateral wall (n ¼ 9), and
in the posterior wall (n ¼ 1) of the LV.
The onset of the E0 was delayed in symptomatic LQTS single-
mutation carriers compared with asymptomatic mutation carriers
and control subjects. Age-corrected E0-wave velocities were
lower in symptomatic than in asymptomatic mutation carriers
[7.9+1.9 vs. 8.9+1.9 cm/s; P ¼ 0.02 (Univariate Analysis of
Variance)].
Subgroup analysis of LQT1 and LQT2 patients (data not pre-
sented) did not show signiﬁcant differences in the echocardio-
graphic parameters.
We wanted to explore the incremental value provided by echo-
cardiography in LQTS mutation carriers. JLNS patients (double
mutation) were considered a separate category and not necessarily
representative of the more common patients with a single
mutation. Therefore, we constructed ROC curves for LQTS
single-mutation carriers exclusively (n ¼ 64). By ROC analysis,
contraction duration identiﬁed single-mutation carriers with a
history of cardiac events with better speciﬁcity and sensitivity
than QTc did (Figure 4). QTc  0.46 s showed a sensitivity of
70% (95% CI 67–88) and a speciﬁcity of 50% (95% CI 40–61)
to identify single-mutation carriers with a history of events. Con-
traction duration identiﬁed single-mutation carriers with a history
of events with a sensitivity of 79% (95% CI 68–87) and a speciﬁcity
of 74% (95% CI 62–83) with an optimal cut off value of 0.44 s
(95% CI by bootstrapping 0.41–0.46). Importantly, contraction
duration was prolonged in all six symptomatic single-mutation car-
riers that exhibited QTc shorter than 0.46 s. Optimal cut-off value
for PEV was 1.65 cm/s (95% CI by bootstrapping 1.24–2.23) and
demonstrated a sensitivity of 70% (95% CI 58–79) and a speciﬁcity
of 68% (95% CI 55–78) for a history of cardiac events in single-
mutation carriers by ROC analysis.
Long QT syndrome double-mutation carriers
QTc was markedly prolonged in double-mutation carriers com-
pared with all other groups (P , 0.001) (Table 1). Contraction dur-
ation was prolonged and PEV augmented compared with healthy
individuals and asymptomatic single-mutation carriers. Mechanical
dispersion was longer than in healthy individuals, but not signiﬁ-
cantly different from single-mutation carriers.
The intra- and interobserver variabilities of PEV measurements
demonstrated an intraclass correlation coefﬁcient of 0.92 (95%
CI 0.84–0.96) and 0.79 (95% CI 0.68–0.86), respectively, and for
contraction duration measurements of 0.97 (95% CI 0.92–0.99)
and 0.92 (95% CI 0.72–0.98), respectively.
Figure 4 Receiver-operating characteristic curves of cardiac
events (documented arrhythmia, syncope, or aborted cardiac
arrest) in 64 single long QT syndrome mutation carriers (33
symptomatic and 31 asymptomatic). Myocardial contraction dur-
ation shows higher sensitivity and speciﬁcity for cardiac events
compared with corrected QT interval. Area under curve 0.77
(95% CI 0.65–0.89) vs. 0.66 (95% CI 0.52–0.79).
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Table 1 Clinical characteristics and echocardiographic results
Healthy
individuals
(n 5 20)
LQTS single-mutation
carrier asymptomatic
(n 5 31)
LQTS single-mutation
carrier symptomatic
(n 5 33)
LQTS double-mutation
(JLNS) carrier symptomatic
(n 5 9)
Individuals on
beta-blocker medication
(n 5 18)
P-value
(ANOVA
F-test)
Clinical characteristics
Age (years) 34+11 41+14 33+15 27+21 59+10 0.04
Women [n (%)] 11 (55) 21 (68) 25 (76) 8 (89) 10 (56)
RR (s) 0.90+0.16 0.93+0.17 0.99+0.19 0.94+0.23 0.93+0.19 0.47
QTc 0.39+0.02 0.46+0.03* 0.48+0.04* 0.56+0.05** 0.41+0.03 ,0.001
Echocardiographic results
EF (%) 67+36 4 +66 4 +66 3 +56 6 +5 0.59
CD by velocity (s) 0.36+0.04 0.40+0.06* 0.46+0.06*
, *** 0.48+0.06*
, *** 0.38+0.04 ,0.001
CD by strain (s) 0.39+0.03 0.45+0.05* 0.49+0.05*
, *** 0.50+0.07*
, *** 0.40+0.03 ,0.001
Standard deviation of
CD by velocity (s)
0.014+0.013 0.031+0.019* 0.048+0.018*
, *** 0.036+0.021* 0.024+0.016 ,0.001
Time to aortic valve
closure (s)
0.36+0.01 0.39+0.03* 0.40+0.03* 0.42+0.05* 0.40+0.03 ,0.001
Peak ejection velocity
(cm/s)
6.2+1.0 6.1+1.1 5.9+0.8 5.5+0.9 5.5+0.9 0.27
PEV (cm/s) 20.2+0.7 1.1+1.3* 2.3+1.3*
, *** 2.5+1.3*
, *** 0.0+0.8 ,0.001
Onset E0 wave (s) 0.40+0.03 0.44+0.04* 0.47+0.05* 0.48+0.07* 0.46+0.04 ,0.001
E0 (cm/s) 9.8+2.3 8.8+2.0 7.9+2.0* 7.8+2.3 9.8+2.7 0.02
E deceleration time (s) 0.15+0.01 0.19+0.03 0.19+0.04 0.23+0.08* 0.20+0.04 0.10
Mean+SD. Right column shows P-values for ANOVA test. Flags for signiﬁcance are obtained from the post hoc pair-wise comparison using the Bonferroni correction.
Results from individuals on beta-blocker medication are not included in the ANOVA analyses.
CD, contraction duration.
*P , 0.05 compared with healthy individuals.
**P , 0.001 compared with each of the other groups.
***P , 0.05 compared with asymptomatic LQTS single-mutation carriers.
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4Discussion
The present study demonstrated that analyses of tissue Doppler
velocities added important information in patients with LQTS. Pro-
longed contraction duration showed better speciﬁcity and sensi-
tivity than QTc as a marker of cardiac events and therefore
provided added value in risk assessment in LQTS mutation car-
riers. The contraction duration showed greater heterogeneity in
LQTS mutation carriers than in controls, reﬂecting dispersion of
myocardial contraction, presumably caused by electrical dispersion
of repolarization. LQTS mutation carriers showed a marked
increase in PEV, indicating myocardial shortening after aortic
valve closure. These ﬁndings were associated with a history of
cardiac events.
Possible mechanisms
In the normal heart, several mechanisms regulate myocyte repolar-
ization. As the QT interval on the surface ECG represents the
summation of action potentials in ventricular myocytes, QT pro-
longation implies action potential prolongation in at least some
portions of the ventricle. A prolongation of the action potential
duration is associated with an increase in the tension developed
by the ventricular muscle, leading to a prolonged contraction.
6–8
In this study, the prolonged contraction in LQTS mutation carriers
was assessed by TDI.
Action potential prolongation can lead to the development of
early EADs, which are oscillations in the membrane potential
before repolarization is complete. EADs may result in a second
contraction and lead to ectopic beats if occurring in a substantial
part of the myocardium.
15 Triggered upstrokes from EADs are a
likely initiating mechanism for torsade de pointes ventricular tachy-
cardia.
16–18 The prolonged contraction duration and the augmen-
ted PEV in LQTS mutation carriers could represent the mechanical
equivalent of an electrical EAD as proposed by De Ferrari et al.
10
This is consistent with the ﬁnding that symptomatic LQTS
mutation carriers had greater PEV than asymptomatic mutation
carriers. EADs may be present at subthreshold levels in LQTS
mutation carriers also in basal conditions, without leading to
arrhythmias but causing contraction prolongation and PEV.
In the majority of our LQTS mutation carriers, we found the
greatest magnitude of the PEV in basal and mid-LV septal
regions. Previous reports have demonstrated that action potentials
of the mid-myocardial cells (M-cells) prolong more than epicardial
or endocardial in response to a lowering of heart rate or to action
potential-prolonging agents.
19 A prolonged action potential leads
to a higher risk of EAD.
15 M-cells have been identiﬁed in the inter-
ventricular septum and in the anterior and lateral walls.
20 The
localization of the reported M-cells matched the regions of the
greatest PEV in our LQTS patients. Therefore, we speculated
that PEV and prolonged contraction assessed by TDI could be a
result of the prolonged action potentials in these M-cells that
are known to have the longest action potential duration.
A possible mechanism of arrhythmia in LQTS patients is
increased dispersion of repolarization.
21 Dispersion of repolariza-
tion may be localized between two different ventricular regions
and as a transmural phenomenon.
22,23 The measurement of
QTc and QT dispersion as indicators of ventricular repolarization
prolongation and dispersion have been widely used during the last
two decades.
24 However, identiﬁcation of the end of the T-wave is
difﬁcult and measurements of dispersion by ECG have modest
reproducibility.
25 The TDI method has the ability to measure
detailed time intervals in different regions of the LV. Our study
clearly demonstrated that the dispersion of mechanical contraction
can be assessed by TDI, as a regional difference in contraction dur-
ation throughout the LV. Furthermore, that mechanical dispersion
was more pronounced in symptomatic compared with asympto-
matic LQTS patients.
Double-mutation carriers, JLNS patients, represent the most
severe clinical phenotype and were therefore analysed separately
in this study. The presence of two mutations (JLNS) is associated
with higher risk of cardiac events and more widespread current
loss.
26 In our study, these facts were supported by a more pro-
longed contraction duration in a greater number of cardiac seg-
ments in JLNS patients compared with single-mutation carriers.
Standard deviation of contraction duration was therefore lower
in the JLNS patients. Pronounced prolongation of contraction dur-
ation may indicate that EADs are the most likely mechanism for
arrhythmia in JLNS patients.
The contraction duration in LQTS mutation carriers exceeded
the time to aortic valve closure. This indicated myocardial contrac-
tion after aortic valve closure, which may be a result of an inhomo-
geneous end of contraction not sufﬁcient to maintain the opening
of the aortic valve. If the dispersion of contraction reﬂects the
electrical dispersion of repolarization, a major arrhythmogenic
factor present in LQTS mutation carriers can be shown by
echocardiography.
A prolonged myocardial contraction will lead to inhomogeneous
and delayed onset of the E0 wave. Furthermore, an inhomogeneous
onset of diastolic lengthening will cause reduced E0 amplitude and
prolonged duration of E0. These assumptions were conﬁrmed in
our study that showed delayed onset of E0, reduced amplitude of
the E0, and prolonged E deceleration time. These ﬁndings imply
an impairment of diastolic function in a number of symptomatic
LQTS mutation carriers.
Previous studies
Echocardiography has traditionally been used to exclude structural
heart disease in LQTS patients. However, Nador et al. presented
an echocardiographic study which showed speciﬁc ventricular
wall abnormalities in 42 LQTS patients.
9 Using M-mode technique,
they demonstrated the occurrence of a slow contraction in the late
myocardial thickening phase. Further they demonstrated a dip in
the later part of contraction followed by a second anterior move-
ment of the endocardium producing a double-peak image. Interest-
ingly, their ﬁndings were associated with a greater probability of
syncope or cardiac arrest. These ﬁndings are conﬁrmed in our
study. We showed that prolonged contraction duration and
increased PEV, which give a similar double-peak pattern, are associ-
ated with cardiac events. Another study has shown mechanical
abnormality by M-mode technique in LQTS patients.
27 Their ﬁnd-
ings were attributed to mechanical dispersion possibly caused
by electrical dispersion of repolarization. A recent case report
indicated mechanical dysfunction in a patient with extreme
QT prolongation.
28 A recent study showed myocardial velocity
LV mechanical dispersion by TDI 335abnormalities in 10 LQTS patients.
29 Our study conﬁrms these
ﬁndings using a new modality of echocardiography. We believe
that TDI measurements may be an easier and more objective
way of quantifying abnormal regional motion than M-mode echo-
cardiography. The study by Nador et al. was followed by a study
giving calcium channel blockers to 10 LQTS patients.
10 Verapamil
abolished the wall motion abnormality, suggesting that sympto-
matic LQTS patients may have an abnormal increase in the intra-
cellular calcium concentration before relaxation has completed,
possibly linked to an EAD, and that the contraction abnormality
may be the mechanical equivalent of an EAD.
Post-systolic shortening after aortic valve closure, which is
similar but not identical to PEV, has been demonstrated in ischae-
mic myocardium
30,31 and may also occur in healthy individuals.
32
PEV in ischaemic heart disease is of greater magnitude compared
with PEV in healthy individuals, and a coexisting reduction in ejec-
tion velocity is obligate.
32 PEV can even be negative if post-systolic
shortening is missing in healthy individuals.
32,33 The LQTS mutation
carriers had normal systolic ejection velocities and ejection frac-
tion. Thus, the elevated PEV in LQTS mutation carriers was not
considered to be a result of earlier cardiac arrests with concomi-
tant myocardial ischaemia.
Clinical implications
QTc is the most rational parameter for screening patients with
unexplained syncope or cardiac arrest. In known LQTS patients,
risk stratiﬁcation is based on the occurrence of previous
syncope, genotype, gender, and QTc.
1 The recent development
from family cascade genetic screening has brought us numerous
LQTS mutation carriers with normal QTc, who would have
been undiagnosed before the genetic era. These asymptomatic
mutation carriers demonstrate neither clinical symptoms nor pro-
longed QTc. Nevertheless, they have increased risk of ventricular
arrhythmia and sudden cardiac death. It is a clinical challenge to
decide whether these asymptomatic mutation carriers should
receive prophylactic treatment or not. Assessment of myocardial
contraction duration may add important information in risk strati-
ﬁcation in LQTS mutation carriers when QTc is normal or mildly
prolonged. Our data showed that myocardial contraction duration
had higher sensitivity and speciﬁcity for a history of cardiac events
than QTc. Importantly, in all symptomatic mutations carriers that
QTc failed to identify, contraction duration by echocardiography
was prolonged ( 0.44 s).
Our study did not provide data that actually demonstrated that
asymptomatic LQTS mutation carriers with prolonged contraction
duration and elevated PEV were more likely to develop arrhyth-
mias than those without. This requires a prospective study in
which asymptomatic untreated patients are followed for an ade-
quate period of time, which is difﬁcult for ethical reasons. Never-
theless, we propose that TDI should become part of the routine
clinical evaluation for LQTS mutation carriers. The myocardial
contraction duration is relatively simple to obtain and has excellent
reproducibility for inter and intra-observations.
Limitations
Prolonged contraction duration by strain in this study was highly sig-
niﬁcant as a risk parameter for cardiac events. However, the results
assessed by myocardial velocities were signiﬁcantly associated with
cardiac events and therefore we preferred velocity to strain
measurements since the reproducibility of this method is superior.
34
Circumferential and radial strains were not analysed in this study.
A limitation of TDI is marked angle dependency, which makes
it sensitive to mal-alignment between the principal direction of
myocardial shortening and the Doppler beam. Owing to less
angle dependency, time interval assessment provided by TDI is a
better reproducible parameter than measurements of velocity
amplitudes.
The association between myocardial mechanical and electrical
dispersion in LQTS mutation carriers should be studied in experi-
mental studies.
Conclusion
This study showed that TDI can be of important value in risk stra-
tiﬁcation of LQTS mutation carriers. Mechanical dispersion of
myocardial contraction assessed by TDI was increased in LQTS
patients. Prolonged myocardial contraction duration and augmen-
ted PEV were better related to cardiac events compared with
QTc. Therefore, we propose that these novel parameters might
be assessed in the management of LQTS patients.
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